CLAIMS

1. Use of an antibody specific for CD19 , wherein the antibody comprises a heavy chain variable region comprising an HCDR1 region of SYVMH (SEQ ID NO:1), an HCDR2 region of NPYNDG (SEQ ID NO:2), and an HCDR3 region of GTYYYGTRVFDY (SEQ ID NO:3), and wherein the antibody comprises a light chain variable region comprising an LCDR1 region of RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region of RMSNLNS (SEQ ID NO:5), and an LCDR3 region of MQHLEYPIT (SEQ ID NO:6), in the manufacture of a medicament for the treatment of a cancer in a human subject, wherein the antibody specific for CD19 is to be administered in combination with a natural killer cell (NK cell).

2. The use according to claim 1, wherein the NK cell is prepared by the following steps (i) to (iii):

step (i) of performing a stationary culture of isolated NK cells in a culture medium containing anti-CD3 antibodies, cytokines, and feeder cells to stimulate intercellular contacts;

step (ii) of adding cytokines, anti-CD3 antibodies, and feeder cells thereto for re-stimulation and performing a stationary culture again to induce intracellular contacts; and

step (iii) of adding a medium containing cytokines to the cells and performing a stationary or suspension culture while constantly maintaining a concentration of the cells and a concentration of the cytokines.

3. The use according to claim 1, wherein the NK cell is prepared by a method comprising co-culturing feeder cells and seed cells, wherein the feeder cells are CD4(+) T cells selected from the group consisting of CD4(+) T cells that have been isolated *ex vivo*, CD4(+) T cells that have been expansion-cultured *ex vivo*, and CD4(+) T cell lines.

4. The use according to claim 3, wherein the CD4(+) T cell lines are CD4(+)/CD1(-) T cell lines.

5. The use according to claim 4, wherein the CD4(+)/CD1(-) T cell lines are H9 or HuT78 cell lines.

6. The use according to claim 3, wherein the seed cells are one or more selected from the group consisting of peripheral blood-derived cells, peripheral blood leukocyte cells, peripheral blood mononuclear cells (PBMCs), umbilical cord blood leukocyte cells, umbilical cord blood mononuclear cells, natural killer cells derived from stem cells, enriched natural killer cells, and isolated natural killer cells.

7. The use according to any one of claims 1 to 6, wherein the cancer is at least one selected from the group consisting of gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, lymphoma, and a malignant tumor of B cell origin.

8. The use according to any one of claims 1 to 7, wherein the heavy chain variable region comprises the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYND GTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG QGTLVTVSS (SEQ ID NO:8) and the light chain variable region comprises the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS NLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:9).

9. The use according to any one of claims 1 to 8, wherein the antibody comprises a heavy chain constant region of ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP ELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:10).

10. The use according to any one of claims 1 to 8, wherein the antibody comprises a light chain constant region of

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:11).

11. The use according to any one of claims 1 to 8, wherein the antibody comprises a heavy chain constant region of ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP ELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:10) and a light chain constant region of RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:11).

12. The use according to any one of claims 1 to 11, wherein the cancer is chronic lymphocytic leukemia.

13. The use according to any one of claims 1 to 11, wherein the cancer is acute lymphoblastic leukemia.

14. The use according to any one of claims 1 to 11, wherein the cancer is a non-Hodgkin’s lymphoma.

15. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is follicular lymphoma.

16. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is small lymphocytic lymphoma.

17. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is mucosa-associated lymphoid tissue lymphoma.

18. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is marginal zone lymphoma.

19. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is diffuse large B-cell lymphoma.

20. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is Burkitt's lymphoma.

21. The use according to claim 14, wherein the non-Hodgkin’s lymphoma is mantle cell lymphoma.